Akeso, Inc. (HK:9926) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Akeso, Inc. has achieved a significant milestone by having its pioneering immunotherapy drugs, Cadonilimab and Ivonescimab, included in China’s National Reimbursement Drug List (NRDL) for the first time. Cadonilimab targets advanced cervical and gastric cancers, while Ivonescimab addresses advanced non-small cell lung cancer, showcasing promising clinical trial results. This inclusion reflects Akeso’s innovative strides in cancer treatment, potentially boosting its market position and investor interest.
For further insights into HK:9926 stock, check out TipRanks’ Stock Analysis page.